See more : Grand River Commerce, Inc. (GNRV) Income Statement Analysis – Financial Results
Complete financial analysis of Citius Pharmaceuticals, Inc. (CTXR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Citius Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- KraussMaffei Company Limited (600579.SS) Income Statement Analysis – Financial Results
- Urja Global Limited (URJA.NS) Income Statement Analysis – Financial Results
- CopperCorp Resources Inc. (CPER.V) Income Statement Analysis – Financial Results
- Estun Automation Co., Ltd (002747.SZ) Income Statement Analysis – Financial Results
- Pinnacle West Capital Corporation (PNW) Income Statement Analysis – Financial Results
Citius Pharmaceuticals, Inc. (CTXR)
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 194.32K | 179.68K | 164.87K | 152.36K | 893.00 | 1.75K | 2.63K | 1.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -194.32K | -179.68K | -164.87K | -152.36K | -893.00 | -1.75K | -2.63K | -1.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 14.82M | 17.66M | 12.24M | 8.81M | 8.60M | 6.56M | 2.94M | 2.93M | 1.80M | 437.97K | 492.14K | 705.81 | 0.00 |
| General & Administrative | 21.91M | 15.66M | 11.29M | 8.90M | 7.00M | 7.23M | 7.05M | 4.52M | 1.43M | 715.03K | 28.12K | 310.30 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.31K | 0.00 |
| SG&A | 21.91M | 15.66M | 11.29M | 8.90M | 7.00M | 7.23M | 7.05M | 4.52M | 1.43M | 715.03K | 28.12K | 19.62K | 25.64K |
| Other Expenses | 0.00 | 1.45M | 59.92K | 110.21K | 715.98K | 1.27M | 732.15K | 732.15K | 486.27K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 36.73M | 33.32M | 23.53M | 17.71M | 15.60M | 13.79M | 9.99M | 7.45M | 3.23M | 1.14M | 28.12K | 19.62K | 25.64K |
| Cost & Expenses | 36.73M | 33.32M | 23.53M | 17.71M | 15.60M | 13.79M | 9.99M | 7.45M | 3.23M | 1.14M | 28.12K | 19.62K | 25.64K |
| Interest Income | 1.18M | 251.40K | 261.83K | 68.07K | 52.66K | 0.00 | 806.00 | 806.00 | 3.07K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 251.40K | 10.84K | 15.67K | 16.44K | 15.84K | 850.79K | 8.99K | 7.50K | 0.00 | 3.25K | 2.39K | 0.00 |
| Depreciation & Amortization | 194.32K | 179.68K | 164.87K | 152.36K | 893.00 | 1.75K | 2.63K | 1.34K | 3.07K | 1.15M | 1.18M | 1.02K | 704.00 |
| EBITDA | -36.73M | -32.88M | -22.88M | -17.38M | -15.54M | -13.79M | -9.98M | -7.45M | -3.23M | 0.00 | 0.00 | -19.62K | -24.93K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -36.73M | -33.32M | -23.53M | -17.71M | -15.60M | -13.79M | -9.99M | -7.45M | -3.23M | -1.15M | -28.12K | -19.62K | -25.64K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.77M | 251.40K | 477.46K | 162.60K | 36.22K | 1.25M | -398.64K | -846.41K | 327.66K | 171.82K | 0.00 | -2.39K | -704.00 |
| Income Before Tax | -31.97M | -33.06M | -23.05M | -17.55M | -15.56M | -12.54M | -10.38M | -8.30M | -2.90M | -1.27M | -31.37K | -22.01K | -26.34K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 576.00K | 576.00K | 70.76K | 125.88K | 16.44K | 1.28M | 850.79K | 8.99K | 4.43K | -119.15K | -1.18M | -1.02K | 0.00 |
| Net Income | -32.54M | -33.64M | -23.13M | -17.67M | -15.58M | -12.54M | -10.38M | -8.30M | -2.90M | -1.27M | -31.37K | -22.01K | -26.34K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.23 | -0.23 | -0.21 | -0.45 | -0.77 | -1.17 | -1.89 | -2.29 | -1.37 | 0.00 | -0.04 | -0.03 | -0.04 |
| EPS Diluted | -0.22 | -0.23 | -0.21 | -0.45 | -0.77 | -1.17 | -1.89 | -2.29 | -1.37 | 0.00 | -0.04 | -0.03 | -0.04 |
| Weighted Avg Shares Out | 146.13M | 146.08M | 108.60M | 39.17M | 20.16M | 10.73M | 5.48M | 3.62M | 2.12M | 0.00 | 750.00K | 750.00K | 750.00K |
| Weighted Avg Shares Out (Dil) | 151.29M | 146.08M | 108.60M | 39.17M | 20.16M | 10.73M | 5.48M | 3.62M | 2.12M | 0.00 | 750.00K | 750.00K | 750.00K |
Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today
7 Reddit Penny Stocks to Watch for Big Upside Ahead
Is It Too Late to Buy Citius Pharmaceuticals Stock?
Which Penny Stocks Are the Best to Buy Right Now? 3 to Watch in 2021
Top 3 Penny Stocks to Buy Right Now for Your 2021 Summer Watchlist
CTXR Stock Price Increases Over 10%: Why It Happened
Citius: Halt For Superiority On The Horizon
Citius Pharmaceuticals Expands Scientific Advisory Board with Addition of Dr. John Laffey, Expert in Stem Cell and Gene Therapies for ARDS
4 Top Biotech Penny Stocks To Watch In The Second Half Of June 2021
Citius Pharmaceuticals to be Added to Russell 2000® Index
Source: https://incomestatements.info
Category: Stock Reports